Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$23.04
+$0.56 · +2.49%
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Previous close
$23.04
+$0.56 · +2.49%
Regular session · ET · Market data may be delayed.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Day range
Current $23.04
52-week range
Current $23.04
Regular session · ET · Market data may be delayed.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Day range
Current $23.04
52-week range
Current $23.04
Third-party consensus; not a GoAI recommendation.
Average target
$52.25
126.78% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
